



CODEN [USA]: IAJPBB

ISSN : 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<https://zenodo.org/records/10434013><https://www.iajps.com/volumes/volume10-december-2023/44-issue-12-december-23/>Available online at: <http://www.iajps.com>

Research Article

METABOLIC ASSOCIATED FATTY LIVER DISEASE (NON-ALCOHOLIC FATTY LIVER DISEASE) AMONG PATIENTS WITH TYPE 2 DIABETES IN SAUDI ARABIA: SYSTEMATIC REVIEW AND META ANALYSIS

Dr Maryam Salman Alsharif¹, Dr saleh saad Alawani², Dr Amer Hassan Alshehri³¹Consultant Family Medicine, Primary Health Care, Ministry of Health (MOH),yanbu , Saudi Arabia, mariumdoctor@gmail.com²Consultant Family Medicine, Primary Health Care, Ministry of Health (MOH),yanbu , Saudi Arabia, saalawani@moh.gov.sa³Consultant Family Medicine, Armed Forces Hospital southwestern region, Saudi Arabia, Mr.shehri87@gmail.com**Abstract:**

Background: Non-alcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes. However, it is often ignored. When co-exist they exacerbate each other serious consequences. No meta-analysis has assessed NAFLD among patients with diabetes in Saudi Arabia. We aimed to investigate the prevalence and predictors of non-alcoholic fatty liver disease among patients with type 2 diabetes in Saudi Arabia.

Methods: three databases were searched (PubMed, MEDLINE, Cochrane Library, and Web of Science for articles published in English from the first published article up to March 2023. The following terms were used: type 2 diabetes, non-alcoholic fatty liver disease, metabolic associated fatty liver disease, predictors, alanine aminotransferase (ALT), aspartate aminotransferase (AST), Saudi Arabia, and using the protean "AND" and "OR".

Results: There were 1139 patients from three cross-sectional studies, ALT was higher among patients with NAFLD, odd ratio, 3.30, 95% CI, 3.12-3.49, P-value <0.001, and the Chi-square was 1.07. No differences were evident between patients with and without NAFLD regarding AST, odd ratio, -0.00, 95% CI, -5.86-5.86, P-value, 1.0, and the Chi-square was 18.03, and HDL, odd ratio, -0.53, 95% CI, -1.21-0.15, P-value, 0.12, and the Chi-square was 77.28. NAFLD prevalence was (40% to 80.8. Conclusion: Non-alcoholic fatty liver disease was prevalent among patients with type 2 diabetes in Saudi Arabia and is associated with high ALT, while, high-density lipoproteins and AST were not. Healthcare and treating physicians might need to screen patients with type 2 diabetes for NAFLD. Further larger studies assessing the bone mineral density at different sites are needed.

Keywords: type 2 diabetes, non-alcoholic fatty liver disease, Saudi Arabia.

Corresponding author:

Dr.Maryam Salman Alsharif,
Consultant Family Medicine,
Primary Health Care, Ministry of Health (MOH),yanbu ,
Saudi Arabia, mariumdoctor@gmail.com



Please cite this article in press Maryam Salman Alsharif et al., *Metabolic Associated Fatty Liver Disease (Non-Alcoholic Fatty Liver Disease) Among Patients With Type 2 Diabetes In Saudi Arabia: Systematic Review And Meta Analysis*, Indo Am. J. P. Sci, 2023; 10 (12).

1. INTRODUCTION:

Diabetes mellitus and non-alcoholic fatty liver disease (NAFLD) are two common chronic diseases that cause a significant burden of morbidity and mortality worldwide. Globally, approximately 10.5% of the population has diabetes, with the Kingdom of Saudi Arabia being among the countries with the highest prevalence of the disease (Sun et al., 2022; Mirghani et al., 2017). NAFLD, a chronic liver disease, has also reached epidemic proportions worldwide, with prevalence ranging from 20% to 30% in the general population (Lee, 2014; Yu et al., 2013).

Non-alcoholic fatty liver disease (NAFLD) is a multi-system disease that affects nearly one-quarter of the global population (Targher et al., 2020). NAFLD is the most common cause of chronic liver disease and non-alcoholic steatohepatitis (NASH), a more severe form of NAFLD, is projected to become the leading cause of liver transplantation (Targher et al., 2020). Beyond its impact on the liver, NAFLD is a serious disease with serious complications, including liver cirrhosis and hepatocellular carcinoma (HCC).

The prevalence of NAFLD in patients with diabetes reported in previous studies ranges from 50% to 87%, and a meta-analysis found that 55.5% of patients with diabetes had NAFLD, with more than one-third progressing to steatohepatitis and approximately 17% developing advanced fibrosis (Lazarus et al., 2022; Al Humayed et al., 2020; Younossi et al., 2019). Despite the potentially fatal consequences of NAFLD, it is often overlooked, especially in the Kingdom of Saudi Arabia, where the situation is particularly concerning, with a projected increase in NAFLD prevalence of 87%, a 187% increasing fibrosis and hepatocellular carcinoma, and 204,000 liver-related death by the year 2030 (Sanai et al., 2021).

A registry-based analysis conducted in Saudi Arabia found that patients with NAFLD had high rates of dyslipidemia (41.7%), diabetes (35.3%), and hypertension (28.4%). Interestingly, these comorbidities were more common in patients with normal levels of alanine aminotransferase (ALT) than in patients with elevated levels (Alswat et al., 2021). The impact of antidiabetic medications on NAFLD is a matter of debate, with some studies demonstrating improvement and others finding no benefit (Kumar et al., 2021; Zafar et al., 2022).

On the other hand, patients with NAFLD (both children and adults) had a high rate of osteoporosis, the released cytokines from the liver, vitamin D, and sedentary life are to blame (Yilmaz et al., 2012).

Thus, the current review aimed to assess non-alcoholic fatty liver disease among patients with diabetes mellitus in Saudi Arabia.

2. Methods:

Eligibility criteria according to PICOS:

A systematic literature search was conducted in four databases; Web of Science, PubMed, SCOPUS, and Cochrane library for relevant articles published in the English language and investigated the prevalence of the metabolic-related fatty liver disease among diabetic patients in Saudi Arabia. The studies from inception up to March 2023 were eligible.

Inclusion criteria:

Studies were eligible if they assessed non-alcoholic fatty liver disease among patients with type 2 diabetes in Saudi Arabia. Prospective, retrospective, cross-sectional, and case-control studies were included.

Exclusion criteria:

Case reports, case series, and animal studies were not included. Abstracts, opinions, letters, editorials, and expert opinions were also excluded.

Outcome measures:

The outcome measure is the prevalence and predictors of non-alcoholic fatty liver disease among patients with type 2 diabetes. The diagnosis of NAFLD was based on ultrasonography.

The literature search:

We searched PubMed, MEDLINE, Cochrane Library, SCOPUS, and Web of Science for articles published in English from the first inception up to February 2023. Two researchers (W. B. and H. M) screened the titles, abstracts, and references of the included studies for relevant articles. Any discrepancy was solved by agreement. The term used were: non-alcoholic fatty liver disease, metabolic associated fatty liver disease, Saudi Arabia, and type 2 diabetes in different combinations using the protean "AND" and "OR".

DATA ANALYSIS:

The most recent RevMan was used. The continuous data were entered manually to test the relationship between NAFL, ALT, AST, and HDL; the fixed or random effects were used depending on the level of heterogeneity. A P-value for the Chi-Square and heterogeneity at <0.05 was considered significant.

Figure 1. Nonalcoholic fatty liver disease and diabetes mellitus, Saudi Arabia




Table 1. Non-alcoholic fatty liver disease among patients with diabetes, Saudi Arabia.

Author	Study type	NAFLD Prevalence	Region	HbA1c	ALT status	AST status
Alamri et al. 2021 [12]	Retrospective , 100 patients	40%	Taif, West	Not mentioned	Raised 17%	Raised in 34%
Alsabaani et al. 2021 [13]	Retrospective , 245 patients	72.8%	Abha, Southwest	8.7	Raised in 10.6%	Raised in 24.9%
Alfadda et al. 2022 [14]	Crosssectional, 490	80.8%	Riyadh, Central	8.3%±1.9	26.5±18.5	21.9±13.7
Al Humayed et al. 2020 [15]	Crosssectional, 237	73.4%	Abha, Southwest	8.7	25.8	20.2
Ajabnoor et al. 2023 [16]	Crosssectional, 67	41.8%	Jeddah, West	8.7 ± 2.1	19.45±11.89	18.57±8.1

Table 2. Non-alcoholic fatty liver disease among patients with diabetes, Saudi Arabia.

Author	Age/years	Females/ males	Obesity and overweight % BMI (mean± SD)	Duration of diabetes	NAFLD association
Alamri et al. 2021 [12]	26-111	53/47	Not mentioned	Not mentioned	Associated with age, high fasting glucose, and low platelets.
Alsabaani et al. 2021 [13]	57.1 ±13.5	61/117	76%	10.1 ± 8.3	Associated with BMI, raised ALT, and HDL
Alfadda et al. 2022 [14]	49.9±7.5	228/262	69.7%	11.46	Associated with BMI, waist circumference, raised ALT, and HDL
Al Humayed et al. 2020 [15]	56.5	80/175	29.9	10.7	Associated with ALT
Ajabnoor et al. 2023 [16]	52±11.25	45/22	94.9%	More than ten years in 58.4%	Associated with diastolic blood pressure and HDL

3. RESULTS:

Characteristics of the included studies:

There were five cross-sectional studies, two were conducted in the West, two were published in the Southwest, and one from Central Region, the studies included patients. The glycated hemoglobin ranged from 8.3 to 8.7, ALT ranged from 19.45 ± 11.89 to 26.5 ± 18.5 and raised from 10.6% to 17%, and AST ranged from 18.57 ± 8.1 to 21.9 ± 13.7 and raised in 24.9% to 34%. Table 1.

In the present study, the age of the patients ranged from 26 to 111 years, 69.7% to 94.9% were obese; the duration of diabetes was 11.46 to 10.1 ± 8.3 years. Prevalence and predictors of non-alcoholic fatty liver disease:

In the present meta-analysis, four studies assessed NAFLD and included 1139 participants. Non-alcoholic fatty liver disease ranged from 40% in the

West (Alamri *et al.*, 2021) to 80.8% in Central Region (Alfadda *et al.*, 2022). High-density lipoproteins and ALT was a predictor of NAFLD, while AST and HDL were not. Table 2 and figures 2-4.

In the present meta-analysis, ALT was higher among patients with NAFLD, odd ratio, 3.30, 95% CI, 3.12-3.49, P-value <0.001, and the Chi-square was 1.07. No heterogeneity was found, $I^2=0.0\%$, and the P-value for heterogeneity, was 0.59. Figure 2.

No differences were evident between patients with and without NAFLD regarding AST, odd ratio, -0.00, 95% CI, -5.86-5.86, P-value, 1.0, and the Chi-square was 18.03. Significant heterogeneity was found, $I^2=89\%$, and the P-value for heterogeneity, 0.0001, and HDL, odd ratio, -0.53, 95% CI, -1.21-0.15, P-value, 0.12, and the Chisquare was 77.28. Significant heterogeneity was found, $I^2=97\%$, and the P-value for heterogeneity, 0.00001. Figures 3 & 4.

Figure 2. A comparison of ALT levels among patients with diabetes with and without NAFLD.




Figure 3. A comparison of AST levels among patients with diabetes with and without NAFLD.





Figure 4. A comparison of HDL levels among patients with diabetes with and without NAFLD.



4. DISCUSSION:

Obesity and diabetes are on the rise in Saudi Arabia, as evidenced by the recent study by Mohamed et al. (2022), which found that one-third of the population will have diabetes by the age of 40. This will have a profound impact on the health of the Saudi population, both in terms of the direct costs of treating these conditions and the indirect costs associated with lost productivity and disability.

A number of studies have found that the prevalence of NAFLD is high among people with diabetes in Saudi Arabia, ranging from 40% to 80.8%. In particular, studies by Alfadda et al. (2022), Alsabaani et al. (2021), and AlHumaid, et al. (2020) found high rates of NAFLD in people with diabetes, highlighting the need for effective intervention and management strategies to address this issue.

Interestingly, the high rates of NAFLD found in Saudi Arabia are similar to those observed in another Gulf country, the United Arab Emirates, where a study by Labenz et al. (2022) found a prevalence of 68.1%. In contrast, a study conducted in Germany by Targher et al. (2020) found a much lower prevalence of 7.8%. These findings suggest that NAFLD may be more common in Gulf countries than in other parts of the world, possibly due to differences in dietary habits and lifestyle.

A systematic review and meta-analysis by Soni et al. (2019) found that the prevalence of NAFLD varied by geographical region, with higher rates in the Middle East and South America and lower rates in Africa. The authors suggested that this variation may be due to differences in genetics, diet, and lifestyle between regions. For example, the Middle East and South America have high rates of obesity, while Africa has a lower prevalence. These differences may also be related to socioeconomic factors and access to healthcare.

In the general population, the prevalence of NAFLD has been estimated at 25.24% (Younossi et al., 2016). Moreover, research has shown that diabetes is associated with a more than two-fold increased risk of developing NAFLD (Jarvis et al., 2020). The high rates of both NAFLD and diabetes, and the link between the two conditions, highlights the importance of addressing these two conditions in an integrated manner. This may involve interventions that target both conditions simultaneously, such as lifestyle changes and pharmacological treatments.

A meta-analysis by Younossi et al. (2019) also reported a high prevalence of NAFLD among patients with diabetes (55.5%), consistent with the results of the current study. However, it is important to note that the included studies in both meta-analyses were conducted in different regions of the world and may have included different patient populations. Therefore, the results should be interpreted with caution and further studies are needed to confirm these findings.

The presence of both NAFLD and diabetes has been shown to increase the risk of developing serious complications, including chronic liver disease, hospitalization, hepatocellular carcinoma, and death (Targher et al., 2007). Furthermore, the combination of NAFLD and diabetes can exacerbate the risk of atherosclerosis through dyslipidemia, hypertension, and poor glycemic control (Bril et al., 2020). This highlights the importance of early diagnosis and intervention for patients with both conditions to minimize the risk of developing these serious complications.

This meta-analysis found that alanine aminotransferase (ALT) levels, but not aspartate aminotransferase (AST) levels, were associated with NAFLD, in line with previous research (Mandal et al., 2018). The meta-analysis also found an association between NAFLD and low high-density lipoprotein (HDL) levels, in agreement with Krishan and colleagues' review of the literature, which found that the dyslipidemia associated with NAFLD and diabetes is atherogenic (Krishan et al., 2017).

The findings from this meta-analysis, and the available literature, suggest that NAFLD is linked to cardiovascular disease, mortality, decreased pulmonary function, and chronic renal failure (Mantovani et al., 2021, 2019, 2019).

Given the potentially serious consequences of NAFLD, it is important to screen for the disease to prevent its progression and associated complications. However, international guidelines on the screening of NAFLD are not uniform, with the European guidelines [21,22] recommending screening for the disease, while the UK National Institute for Care Excellence (NICE) and the American Association for the Study of Liver Diseases (AASLD) are not recommend as a screening for NAFLD, as there is uncertainty about how to interpret the results, the cost-effectiveness of screening, and the role of pharmacological interventions [23,24].

5. CONCLUSION:

Nonalcoholic fatty liver was prevalent among patients with type 2 diabetes in Saudi Arabia. Increasing awareness about NAFLD among patients with type 2 diabetes is recommended. Healthcare and treating physicians might need to screen patients with type 2 diabetes for NAFLD for better selection of the optimal antidiabetic medication. Further larger studies assessing the synergistic effects of diabetes and non-alcoholic fatty liver are needed.

Acknowledgment: We would like to acknowledge the Saudi Digital Library for accessing the data.

Author Contributions: All authors contributed evenly with regard to the development of the study design, data collection, and analysis, interpretation of data, drafting of the manuscript, and critical revision. **Informed consent:** not applicable

Ethical approval: not applicable

Funding: Self-funded

Conflict of interest: The authors declare that there is no conflict of interest.

Data and materials availability: All data sets collected during this study are available upon reasonable request from the corresponding author

REFERENCES:

1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract.* 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119.
2. Mirghani HO. Distress and psychopathology among Sudanese patients with type 2 diabetes mellitus and its relation to glycaemic control. *J Taibah Univ Med Sci.* 2017 Apr 5;12(4):298-303. doi: 10.1016/j.jtumed.2017.02.007.
3. Targher G. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? *Hepatobiliary Surg Nutr.* 2020 Apr;9(2):239-241. doi: 10.21037/hbsn.2019.10.21.
4. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, CortezPinto H, Crespo

- J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol.* 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4.
5. Al Humayed SM, Sabaani AAA, Mahfouz AA, Awadalla NJ, Musa MJ, Patel A. Clinical and Biochemical Predictors of Nonalcoholic Fatty Liver Disease among Type 2 Diabetes Mellitus Patients at Primary Health Care Level in South Western Saudi Arabia. *Diagnostics (Basel).* 2020 Oct 12;10(10):809. doi: 10.3390/diagnostics10100809. NAFLD 174/237.
6. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. *J Hepatol.* 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021.
7. Sanai FM, Al Khathlan A, Al Fadhli A, Jazzar AS, Hashim AM, Mansour E, Abaalkhail F, Hasan F, Al Mudaiheem H, Al Quraishi H, Bottomley J, Alswat KA, Al Ghamdi M, Farghaly M, Fathy M, Awad N, Mohamed O, Kozma S, AlHamoudi W, Al-Jedai A. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates, and Kuwait. *Hepatol Int.* 2021 Aug;15(4):912-921. doi: 10.1007/s12072-021-10182-x.
8. Alswat K, Sanai FM, Al-Hamoudi W, Ismail M, Dahlan Y, AlGhamdi HS, Altraif I, Alalwan A, Babatin MMA, Alqahtani SA. Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. *Diabetes Metab Syndr Obes.* 2021 Mar 16;14:1167-1175. doi: 10.2147/DMSO.S300051.
9. Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, Kumar S, Siddiqi TJ, Usman MS.. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. *Dig Liver Dis.* 2021 Jan;53(1):44-51. doi: 10.1016/j.dld.2020.08.021.
10. Zafar Y, Rashid AM, Siddiqi AK, Ellahi A, Ahmed A, Hussain HU, Ahmed F, Menezes RG,

- Siddiqi TJ, Maniya MT. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Clin Res Hepatol Gastroenterol*. 2022 Aug-Sep;46(7):101970. doi: 10.1016/j.clinre.2022.101970.
11. Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis-clinical and molecular crosstalk. *Aliment Pharmacol Ther*. 2012 Aug;36(4):345 -52. doi: 10.1111/j.1365-2036.2012.05196.x.
 12. Alamri AS, Alhomrani M, Alsanie WF, Alghamdi AJ, Alghamdi ZM, AlSubaie AA, Alharthi YA, Alqurashi HH, Asdaq SMB. Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. *Saudi J Biol Sci*. 2021 Sep;28(9):49214925. doi: 10.1016/j.sjbs.2021.05.063.
 13. Alsabaani AA, Mahfouz AA, Awadalla NJ, Musa MJ, Al Humayed SM. NonAlcoholic Fatty Liver Disease among Type-2 Diabetes Mellitus Patients in Abha City, South Western Saudi Arabia. *Int J Environ Res Public Health*. 2018 Nov 11;15(11):2521. doi: 10.3390/ijerph15112521.
 14. Alfadda AA, Sherbeeni SM, Alqutub AN, Aldosary AS, Aldaghri NM, Taylor-Robinson SD, et al. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study. *Saudi J Gastroenterol*. 2022 May 23. doi: 10.4103/sjg.sjg_73_22.
 15. Al Humayed SM, Sabaani AAA, Mahfouz AA, Awadalla NJ, Musa MJ, Patel A. Clinical and Biochemical Predictors of Nonalcoholic Fatty Liver Disease among Type 2 Diabetes Mellitus Patients at Primary Health Care Level in South Western Saudi Arabia. *Diagnostics (Basel)*. 2020 Oct 12;10(10):809. doi: 10.3390/diagnostics10100809.
 16. Ajabnoor GMA, Bahijri SM, Enani SM, Alsheikh L, Ahmed M, Alhozali A, AlShali K, Eldakhakhny BM, Alamoudi AA, Al-Ahmadi J, Borai A, Al-Mowallad AS, Tuomilehto J. Exploring the Validity of Available Markers and Indices in the Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) in People with Type 2 Diabetes in Saudi Arabia. *Diseases*. 2023 Jan 15;11(1):10. doi: 10.3390/diseases11010010.
 17. Mohamed AM, Isa HM, Ali MS, Dadi A, Kadhim Z. Prevalence of Nonalcoholic Fatty Liver Disease among Patients with Diabetes Mellitus Attending Primary Health Care Centers in Bahrain. *Oman Med J*. 2022 Mar 22;37(2):e350. doi: 10.5001/omj.2022.53.
 18. Labenz C, Kostev K, Alqahtani SA, Galle PR, Schattenberg JM. Impact of NonAlcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. *Exp Clin Endocrinol Diabetes*. 2022 Mar;130(3):172-177. doi: 10.1055/a-1378-4679.
 19. Targher G. Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? *Hepatobiliary Surg Nutr*. 2020 Apr;9(2):239-241. doi: 10.21037/hbsn.2019.10.21.
 20. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.
 21. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of populationbased observational studies. *PLoS Med*. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100
 22. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. *J Hepatol*. 2019 Oct;71(4):793-801. doi: 10.1016/j.jhep.2019.06.021.
 23. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2007;30:1212-8. doi: 10.2337/dc06-2247
 24. Bril F. Nonalcoholic fatty liver disease in type 2 diabetes: awareness is the first step toward change. *Hepatobiliary Surg Nutr*. 2020 Aug;9(4):493-496. doi: 10.21037/hbsn.2019.11.11.
 25. Mandal A, Bhattarai B, Kafle P, Khalid M, Jonnadula SK, Lamichhane J, Kanth R, Gayam V. Elevated Liver Enzymes in Patients with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease. *Cureus*. 2018 Nov 23;10(11):e3626. doi: 10.7759/cureus.3626.

26. Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2021 Nov;6(11):903-913. doi: 10.1016/S24681253(21)00308-3.
27. Mantovani A, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, Loomba R, Tilg H, Byrne CD, Fabbri L, Targher G. Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. *Diabetes Metab*. 2019 Dec;45(6):536-544. doi: 10.1016/j.diabet.2019.04.008.
28. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut*. 2022 Jan;71(1):156-162. doi: 10.1136/gutjnl-2020-323082.
29. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388-402. 10.1016/j.jhep.2015.11.004
30. Italian Association for the Study of the Liver (AISF) AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. *Dig Liver Dis* 2017;49:471-83. 10.1016/j.dld.2017.01.147
31. Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. *BMJ* 2016;354:i4428. 10.1136/bmj.i4428
32. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018;67:328-57. 10.1002/hep.29367
33. Xie R, Liu M. Relationship Between Non-Alcoholic Fatty Liver Disease and Degree of Hepatic Steatosis and Bone Mineral Density. *Front Endocrinol (Lausanne)*. 2022 Mar 14;13:857110. doi: 10.3389/fendo.2022.857110.